The global continuous renal replacement therapy market was valued at $1,249.21 million in 2021, and is projected to reach $2,622.44 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.
Continuous renal replacement therapy (CRRT) is a slow and smooth continuous extracorporeal blood purification process. It is usually implemented over 24 hours to several days with gentle removal of fluid and excess uremic toxins. This technique is usually based on the physiological principles of diffusion, ultrafiltration, convection, and adsorption.
The key factors which drive the growth of the market are a rise in the incidence of Acute Kidney Injury (AKI), an increase in the incidence of sepsis and a rise in the adoption of various key strategies by key players operating in the market.
In addition, the rise in the demand for continuous renal replacement therapy worldwide is the major factor that boosts the growth of the market. For instance, in February 2021, the Journal Kidney360 stated that demand for renal replacement therapy increased during the COVID-19 pandemic.
However, lack of awareness and high costs associated with CRRT devices in developing countries are the key factors likely to hamper the growth of the market. In addition, the rise in government initiatives for regulatory approval is anticipated to provide lucrative opportunities to key players operating in the market.
The continuous renal replacement therapy market is segmented on the basis of product, modality, age group, and region. Depending on product, the market is classified into dialysates and replacement fluids, disposables, and CRRT systems. Disposables segment is further classified as hemofilters, bloodline sets and tubes, and other disposables. By modality, the market is classified into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). According to age group, the market is segmented into pediatric, and adults.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Asia-Pacific accounted for the largest market share in the continuous renal replacement therapy market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to an increase in the number of initiatives along with enhanced investments for the overall R&D of CRRT products. In addition, the surge in the focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture potential growth opportunities boosts the market.
The report provides a comprehensive analysis of the key players that operate in the global continuous renal replacement therapy market. The key companies profiled in the report include Anjue Medical Equipment Co. Ltd., Asahi Kasei Corporation, B. Braun Melsungen AG, Chongqing Shanwaishan Science and Technology Co. Ltd., Cytosorbents, Infomed SA, Medica S.p.A, Medical Components Inc., Medites Pharma spol. s.r.o., Medtronic plc., Nikkiso Co. Ltd., Ningbo Tianyi Medical Devices Co. Ltd., Nipro Corporation, SWS Hemodialysis Care Co. Ltd., Toray Industries Inc., Baxter International Inc., and Fresenius Medical Care AG & Co. KGaA.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the continuous renal replacement therapy market analysis from 2021 to 2031 to identify the prevailing continuous renal replacement therapy market opportunities.
- Market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the continuous renal replacement therapy market segmentation assists in determining the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes an analysis of the regional as well as global continuous renal replacement therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Dialysates and Replacement Fluids
- Disposables
- Type
- Hemofilters
- Bloodline Sets Tubes
- Other Disposables
- CRRT Systems
By Modality
- Slow Continuous Ultrafiltration (SCUF)
- Continuous Venovenous Hemofiltration (CVVH)
- Continuous Venovenous Hemodiafiltration (CVVHDF)
- Continuous Venovenous Haemodialysis (CVVHD)
By Age Group
- Adults
- Pediatrics
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of LAMEA
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Fresenius Medical Care
- Baxter International
- Toray Industries Inc.
- SWS Hemodialysis Care
- Nipro Corporation
- Ningbo Tianyi Medical Devices
- NIKKISO Co. Ltd
- Medtronic plc
- Medites Pharma spol. s.r.o
- Medical Components Inc.
- Medica S.p.A
- Infomed SA
- Cytosorbents
- Chongqing Shanwaishan Science and Technology
- B. Braun Melsungen Ag
- Asahi Kasei Corporation
- Anjue Medical Equipment Co. Ltd
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
Executive Summary
According to the report, titled, “Continuous Renal Replacement Therapy Market," the Continuous Renal Replacement Therapy Market Size was valued at $1.3 billion in 2021 and is estimated to reach $2.6 billion by 2031, growing at a CAGR of 7.7% from 2022 to 2031.
Continuous renal replacement therapy (CRRT) is a slow and smooth continuous extracorporeal blood purification, which is designed to replicate the depurative function of the kidney. It is usually implemented over 24 hours to several days with an aim of gentle correction of fluid overload and removal of excess uremic toxins. It represents a better modality for the management of severe acute chronic injury.
Continuous Renal Replacement Therapy Market Trends are rising in the incidence of acute kidney injury (AKI) across the world. For instance, according to the International Society of Nephrology (INR), an estimated 13.3 million cases of AKI are registered annually worldwide. This is anticipated to boost the adoption of continuous renal replacement therapy at a rapid rate. With the rapid growth in the geriatric population globally, the prevalence of kidney-related diseases is expected to increase significantly. This, in turn, is expected to propel the growth of the CRRT market at a significant rate during the forecast period.
Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the CRRT market. According to an article published by the Journal of Clinical and Diagnostic Research (JCDR) 2018, in a prospective observational study conducted on 100 critically ill patients In India, AKI was observed in 17.3 cases/1,000 persons. To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers. Additionally, regulatory policies in the Asia Pacific region are more adaptive and business friendly due to the less-stringent data requirements. This, along with the increasing competition in the mature markets (Europe, Japan, and Australia), will further encourage CRRT product manufacturers to focus on the emerging market.
However, as the population in emerging nations is price-sensitive, they prefer lower-priced products. Although the cost of CRRT in developing countries is high which makes these procedures are still unaffordable for a large portion of the population due to the low purchasing power. This limits the demand and uptake of CRRT in developing as well as developed countries. CRRT is a highly specialized and critical therapy that involves complex nursing care. Properly trained ICU nurses are required for the continuous assessment of indications, ensuring good vascular access, avoiding unnecessary interruptions, and preventing complications in patients during CRRT. However, currently, there is a dearth of registered nurses in ICU settings. Moreover, the complexity associated with CRRT is likely to hinder the market growth.
The Continuous Renal Replacement Therapy Market Size was valued at $1.3 billion in 2021 and is estimated to reach $2.6 billion by 2031, growing at a CAGR of 7.7% from 2022 to 2031. The Continuous Renal Replacement Therapy Market is Segmented on the basis of product, modality, age group, and region. Depending on the product, the market is classified into dialysates and replacement fluids, disposables, and CRRT systems. The disposables segment is further classified as hemofilter, bloodline sets and tubes, and other disposables. By modality, the market is classified into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), and continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). According to age group, the market is segmented into pediatrics and adults.
Region wise, Continuous Renal Replacement Therapy Market Analysis is done across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By product, the dialysates and replacement fluids segment generated the highest Continuous Renal Replacement Therapy Market Share in 2021 owing to a rise in the incidence of acute kidney injury.
By modality, the continuous venovenous hemofiltration (CVVH) segment generated the highest revenue in the continuous renal replacement therapy market in 2021, as CVVH can remove large volumes of fluid while avoiding the hypotensive episodes caused by intermittent hemodialysis and its intermittent removal of large volumes of fluid.
By age group, the adult segment generated the highest revenue in the Continuous Renal Replacement Therapy industry in 2021, owing to various regulatory approvals for the adult CRRT, and a rise in the development of novel products for CRRT. Along with this, the adoption of various growth strategies by various market players is creating lucrative opportunities in the segment.
By region, Asia-Pacific accounted for the largest market share in the Continuous Renal Replacement Therapy industry in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to an increase in the number of initiatives along with enhanced investments for the overall R&D of CRRT products. In addition, the surge in the focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture potential growth opportunities boosts the growth of the market.
The report provides a comprehensive analysis of the key players that operate in the global continuous renal replacement therapy market. The key companies profiled in the report include Anjue Medical Equipment Co. Ltd., Asahi Kasei Corporation, B. Braun Melsungen AG, Chongqing Shanwaishan Science and Technology Co. Ltd., Cytosorbents, Infomed SA, Medica S.p.A, Medical Components Inc., Medites Pharma spol. s.r.o., Medtronic plc., Nikkiso Co. Ltd., Ningbo Tianyi Medical Devices Co. Ltd., Nipro Corporation, SWS Hemodialysis Care Co. Ltd., Toray Industries Inc., Baxter International Inc., and Fresenius Medical Care AG & Co. KGaA.
Key Findings of the Study
- On the basis of product, the dialysates and replacement fluids segment held a 56.23% share in the global market in 2021.
- On the basis of modality, the continuous venovenous hemofiltration (CVVH) segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
- On the basis of age group, the adult segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
- Region wise, Asia-Pacific is expected to experience the highest market share during the forecast period. This was attributed to an increase in the number of initiatives along with enhanced investments for the overall R&D of CRRT products. In addition, the surge in the focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture potential growth opportunities boosts the market.
Companies Mentioned
- Fresenius Medical Care
- Baxter International
- Toray Industries Inc.
- Sws Hemodialysis Care
- Nipro Corporation
- Ningbo Tianyi Medical Devices
- Nikkiso Co. Ltd
- Medtronic plc
- Medites Pharma Spol. S.R.O
- Medical Components Inc.
- Medica S.P.A
- Infomed Sa
- Cytosorbents
- Chongqing Shanwaishan Science and Technology
- B. Braun Melsungen AG
- Asahi Kasei Corporation
- Anjue Medical Equipment Co. Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 323 |
| Published | August 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1249.21 million |
| Forecasted Market Value ( USD | $ 2622.44 million |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
